Latest news with #Entyvio
The Star
4 days ago
- Health
- The Star
More flexible biologics option for IBD patients now available
IBD is a chronic condition affecting the gastrointestinal system that has no cure, but treatment can help control its symptoms. — AFP Inflammatory bowel disease (IBD) patients who are resistant to or cannot tolerate conventional treatment now have a more flexible biologics option available to them. Entyvio (generic name vedolizumab) is now available as a self-administered injection for cases of moderately-to-severely active IBD in those aged 18 and above who had an inadequate response with, lost response to, or were intolerant to, either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist. This biologic was previously only available via intravenous (IV) insfusion. Patients who have received at least two prior IV infusions of Entyvio may also switch to the injectable version for their maintenance therapy. IBD includes both Crohn's disease, a condition that can affect the entire gastrointestinal tract, and ulcerative colitis, which specifically affects the colon and rectum. Treatment with the new formulation helped 48% of patients with Crohn's disease and 46.2% of patients with ulcerative colitis achieve clinical remission in one year. IBD is a chronic condition with no cure, but ongoing treatment can help patients achieve remission and manage symptoms that impact their quality of life. In Malaysia, the incidence of IBD has been steadily increasing over the past few decades. Once considered a predominantly Western disease, IBD is now emerging more prominently in Asia, including Malaysia. IBD patients often endure debilitating symptoms such as abdominal pain, chronic diarrhoea, rectal bleeding and weight loss. These symptoms can severely affect their quality of life and compromise every aspect of their well-being, from physical and psychological to familial and social aspects. 'Without timely intervention to achieve disease remission, patients may continue to suffer, incur rising healthcare costs, and face serious complications, including an increased risk of colorectal cancer,' said senior consultant gastroenterologist Prof Dr Raja Affendi Raja Ali. A range of treatments are available to help reduce inflammation, with conventional therapies commonly used for mild to moderate symptoms. "With Entyvio® Pen, patients have the option of administering their maintenance treatment at home or on-the-go,' said Takeda Malaysia and Singapore general manager Simon Gallagher. 'Our development of a subcutaneous [below the skin] option demonstrates Takeda's commitment to addressing the very real needs of those living with IBD. "By expanding treatment choices, we aim to empower patients and healthcare providers with medicine that support long-term disease management and an improved quality of life.'
Yahoo
10-06-2025
- Business
- Yahoo
Odyssey bails on public listing as US IPO landscape stutters
Odyssey Therapeutics is unlikely to join the 2025 class of biotechs hitting the stock exchanges after the company withdrew its registration statement for an initial public offering (IPO). The autoimmune and inflammatory disease specialist was one in a wave of biotechs to reveal IPO ambitions in January 2025. While Sionna Therapeutics, a biopharma that filed IPO paperwork at the same time, went on to close a nearly $220m IPO in February, Odyssey has bailed on a public listing. Odyssey did not disclose the number of its common stock shares it was offering, nor the price at which the IPO would conduct on each share. The Form S-1, a registration form with the US Securities and Exchange Commission (SEC) for companies carrying out public offerings, only mentioned that the listing would have occurred on the Nasdaq. Odyssey was eyeing an IPO as a way to fund its pipeline, headed by RIPK2 inhibitor OD-07656 that was set for Phase II trials for ulcerative colitis treatment, both as a monotherapy and in combination with Takeda's blockbuster Entyvio (vedolizumab). As per its IPO prospectus in January, the monotherapy trial was set to commence in Q1 2025, with the combo trial slated for the same quarter in 2026. Two pre-clinical programmes also stood to benefit from cash generated from the IPO. In its notice to the SEC outlining the withdrawal of the registration statement, Odyssey stated it is because it is 'not in the best interests of the company to conduct the proposed offering at this time'. The IPO U-turn is the first sign that the health of the IPO landscape could be suffering in the wake of economic fallout from US President Donald Trump's policies. Indeed, it consolidates predictions made by one GlobalData analyst earlier this year. In April, GlobalData business fundamentals analyst Alison Labya said: 'The Trump administration has introduced uncertainty to the biopharmaceutical industry across healthcare policies, drug pricing reforms, and regulatory frameworks, all of which could impact investor confidence. 'Additionally, Trump's recent tariff announcement on imports from Canada, Mexico, and China has led to increased market volatility, potentially delaying IPOs as investors await the countries' responses to the tariffs.' Biotech IPOs saw a strong recovery in 2024, with a total raise of $8.52bn, up 68.4% from $5.06bn raised in 2023. It was the highest total IPO value raised since 2021, with the rebound driven by US Federal Reserve interest rate cuts. The uptick continued into 2025, with Sionna joined by Maze Therapeutics and Metsera Therapeutics. U-turning on IPOs is rare, but Odyssey is not the only biotech to bail on a public listing in the past year. Australian biotech Telix Pharmaceuticals withdrew its US public listing at the last minute in June 2024, also citing unfavourable market conditions at the time. "Odyssey bails on public listing as US IPO landscape stutters" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
